Rabeprazole Sodium Patent Expiration
Rabeprazole Sodium is Used for treating peptic ulcers. It was first introduced by Waylis Therapeutics Llc
Rabeprazole Sodium Patents
Given below is the list of patents protecting Rabeprazole Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Aciphex |
US5045552 (Pediatric) | Pyridine derivatives having anti-ulcerative activity |
Nov 08, 2013
(Expired) | Waylis Therap |
| Aciphex Sprinkle |
US5045552 (Pediatric) | Pyridine derivatives having anti-ulcerative activity |
Nov 08, 2013
(Expired) | Aytu |
| Aciphex | US5045552 | Pyridine derivatives having anti-ulcerative activity |
May 08, 2013
(Expired) | Waylis Therap |
| Aciphex Sprinkle | US5045552 | Pyridine derivatives having anti-ulcerative activity |
May 08, 2013
(Expired) | Aytu |
Rabeprazole Sodium's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Rabeprazole Sodium:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE1 |